H.C. Wainwright raised the firm’s price target on Oric Pharmaceuticals to $16 from $13 and keeps a Buy rating on the shares. The analyst says ORIC-114 appears to show a differentiated clinical profile relative to competitors in dose escalation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ORIC:
- Oric Pharmaceuticals price target raised to $17 from $14 at JPMorgan
- Oric Pharmaceuticals price target raised to $15 from $13 at Citi
- Oric announces initial data from ongoing ORIC-114 Phase 1 dose escalation
- Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
- ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023